MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414453 | Name: Nolatrexed Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nolatrexed Free Base is a thymidylate synthase inhibitor.

Chemical Structure

Nolatrexed Free Base
Nolatrexed Free Base
CAS#147149-76-6 (free base)

Theoretical Analysis

MedKoo Cat#: 414453

Name: Nolatrexed Free Base

CAS#: 147149-76-6 (free base)

Chemical Formula: C14H12N4OS

Exact Mass: 284.0732

Molecular Weight: 284.34

Elemental Analysis: C, 59.14; H, 4.25; N, 19.70; O, 5.63; S, 11.28

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
152946-68-4 (HCl salt); 147149-76-6 (free base)
Synonym
Nolatrexed Free Base
IUPAC/Chemical Name
2-Amino-6-methyl-5-(4-pyridylthio)-4(3H)-quinazolinone.
InChi Key
XHWRWCSCBDLOLM-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)
SMILES Code
O=C1NC(N)=NC2=C1C(SC3=CC=NC=C3)=C(C)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 284.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zheng J, Lin J, Wang L, Zhou J, Xie B, Xu T, Zhang W. Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil. Oncol Res Treat. 2014;37(10):540-4. doi: 10.1159/000368107. Epub 2014 Sep 16. PMID: 25342504. 2: Hughes AN, Rafi I, Griffin MJ, Calvert AH, Newell DR, Calvete JA, Johnston A, Clendeninn N, Boddy AV. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. Clin Cancer Res. 1999 Jan;5(1):111-8. PMID: 9918208. 3: Hughes AN, Griffin MJ, Newell DR, Calvert AH, Johnston A, Kerr B, Lee C, Liang B, Boddy AV. Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. Br J Cancer. 2000 May;82(9):1519-27. doi: 10.1054/bjoc.2000.1172. PMID: 10789718; PMCID: PMC2363406. 4: Pivot X, Wadler S, Kelly C, Ruxer R, Tortochaux J, Stern J, Belpomme D, Humblet Y, Domenge C, Clendeninn N, Johnston A, Penning C, Schneider M. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Ann Oncol. 2001 Nov;12(11):1595-9. doi: 10.1023/a:1013185402896. PMID: 11822760. 5: Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;44(4):307-11. doi: 10.1007/s002800050982. PMID: 10447578. 6: Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb;25(1):85-94. doi: 10.1007/s10637-006-9003-x. Epub 2006 Sep 7. PMID: 16957834. 7: Estlin EJ, Pinkerton CR, Lewis IJ, Lashford L, McDowell H, Morland B, Kohler J, Newell DR, Boddy AV, Taylor GA, Price L, Ablett S, Hobson R, Pitsiladis M, Brampton M, Clendeninn N, Johnston A, Pearson AD. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation. Br J Cancer. 2001 Jan 5;84(1):11-8. doi: 10.1054/bjoc.2000.1569. PMID: 11139306; PMCID: PMC2363615. 8: Jodrell DI, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor GA, Johnston A, Clendeninn NJ. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20. doi: 10.1038/sj.bjc.6690146. PMID: 10070890; PMCID: PMC2362691. 9: Wang GF, Zhang JY, Wu SY, Xu W, Wan SH, Shao CF, Zhang JJ. [Measurement of plasma concentration and bioavailability of nolatrexed dihydrochloride in mice]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Nov;28(11):1993-5. Chinese. PMID: 19033111. 10: Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75. doi: 10.1200/JCO.2006.08.4046. PMID: 17634485.

View History

Locicortolone dicibate

Locicortolone dicibate

LN5535

LN5535

LN5972

LN5972